Skip to main content
. 2004 Aug 3;101(33):12171–12176. doi: 10.1073/pnas.0403341101

Fig. 5.

Fig. 5.

Kinetics of TAP-Imd3 activity and MPA inhibition. TAP-Imd3 purified from DY1100 was assayed for IMPDH activity at 1 mM IMP while varying NAD+ (A) or at 1.8 mM NAD+ while varying IMP (B). (C) TAP-Imd2 (from DY423) and TAP-Imd3 (DY1103) were purified and assayed for enzyme activity at 2 mM NAD+ and 0.5 mM IMP in the presence of increasing amounts of MPA. Activity was set at 100% for the samples without drug (n = 3 for Imd3 and n = 7 for Imd2). The drug-containing reactions (n = 3 for Imd3 and n = 7 for all Imd2 points except 25 μM, which was n = 4) were expressed as a percentage of this control and averaged. Error bars represent the SEM. Under these conditions, the absolute specific activity of Imd2 was approximately one-fourth that of Imd3 in the absence of drug.